News

Patients with HBV inadequately monitored for disease activity


 

FROM CLINICAL INFECTIOUS DISEASES

Chronic hepatitis B virus patients are insufficiently monitored for disease activity and hepatocellular carcinoma (HCC), according to Philip R. Spradling, MD, and his associates of the Centers for Disease Control and Prevention.

This negatively stained transmission electron micrograph revealed the presence of numerous hepatitis B virus virions, also know as Dane particles. HBV contains a genome of DNA. Betty Partin/CDC

This negatively stained transmission electron micrograph revealed the presence of numerous hepatitis B virus virions, also know as Dane particles. HBV contains a genome of DNA.

In a cohort study of 2,992 patients with CHB, 2,338 were used for assessment. Researchers used alanine aminotransferase (ALT) monitoring, HBV DNA monitoring, assessment for cirrhosis, and HBV antiviral therapy for examination. For ALT monitoring, 1,814 (78%) of patients had at least one ALT level obtained per year of follow-up. Only 876 patients (37%) had at least one HBV DNA level assessment per year of follow-up and 1,037 (44%) had less than annual testing, and 18% of patients never had an HBV DNA level assessed. Among patients with cirrhosis, 297 (54%) had HBV DNA testing done at least annually, 189 (35%) had testing done but less frequently than annually, and 61 (11%) never had an HBV DNA test done. And of the 547 patients with cirrhosis, 305 (56%) were prescribed HBV antiviral therapy.

It was noted that patients were monitored during 2006-2013. Only 68% of patients had not been prescribed treatment, and 72% had received liver-related specialty care.

“Our findings reiterate the need for clinicians who treat patients with [chronic HBV] to provide ongoing, continual assessment of disease activity based on HBV DNA and ALT levels, as well as liver imaging surveillance among patients at high risk for HCC,” researchers concluded. “As antiviral therapy for [chronic HBV] now includes potent and highly efficacious oral agents that have few contraindications and minimal side effects, as well as a high barrier to resistance, clinicians should be vigilant for opportunities to decrease the likelihood of poor clinical outcomes.”

Read the full study in Clinical Infectious Diseases here.

llaubach@frontlinemedcom.com

Recommended Reading

Hepatitis C infection rates rising in women, young children
MDedge Infectious Disease
WHO analysis: Cost of new HCV meds unaffordable globally
MDedge Infectious Disease
Deals likely the way forward for Medicaid coverage of hepatitis C drugs
MDedge Infectious Disease
Elbasvir-grazoprevir works effectively against HCV despite current drug use
MDedge Infectious Disease
Study finds clues to fibrosis progression in chronic HCV infection
MDedge Infectious Disease
Anal cancer in HIV-infected patients: to screen or not?
MDedge Infectious Disease
Healthy donor stool safe, effective for recurrent CDI
MDedge Infectious Disease
Younger age, inconsistency of care affect antiviral adherence in hepatitis B
MDedge Infectious Disease
Rotavirus vaccine again linked to small increase in risk of intussusception hospitalization
MDedge Infectious Disease
Ombitasvir/paritaprevir-based HCV regimens perform well in HIV coinfection
MDedge Infectious Disease